| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
37,490,000 |
| Market
Cap: |
26.24(K) |
| Last
Volume: |
125 |
Avg
Vol: |
35,949 |
| 52
Week Range: |
$0.0002 - $0.0044 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Affymax is a biopharmaceutical company in the process of restructuring operations. Co.'s U.S. Food and Drug Administration approved product, OMONTYS® (peginesatide) Injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis, has been recalled. As a result of the voluntary recall of OMONTYS, all marketing activities were suspended and sales were ceased. Co. granted its collaboration partner, Takeda Pharmaceutical Company Limited, a license to OMONTYS.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Duliege Anne-Marie |
Chief Medical Officer |
• – – |
2012-11-01 |
4 |
AS |
$22.90 |
$24,182 |
D/D |
(1,056) |
23,125 |
|
- |
|
| Venteicher Robert |
SVP, Technical Operations |
• – – |
2012-10-23 |
4 |
AS |
$25.74 |
$21,441 |
D/D |
(833) |
24,994 |
|
- |
|
| Venteicher Robert |
SVP, Technical Operations |
• – – |
2012-10-23 |
4 |
OE |
$5.83 |
$4,856 |
D/D |
833 |
25,827 |
|
- |
|
| Knapp Jeffrey H |
Chief Commercial Officer |
• – – |
2012-10-15 |
4 |
AS |
$26.71 |
$267,370 |
D/D |
(10,012) |
13,125 |
|
- |
|
| Knapp Jeffrey H |
Chief Commercial Officer |
• – – |
2012-10-15 |
4 |
OE |
$6.23 |
$175,899 |
D/D |
10,012 |
23,137 |
|
- |
|
| Venteicher Robert |
SVP, Technical Operations |
• – – |
2012-10-15 |
4 |
AS |
$27.00 |
$1,138,671 |
D/D |
(42,173) |
24,994 |
|
- |
|
| Venteicher Robert |
SVP, Technical Operations |
• – – |
2012-10-15 |
4 |
OE |
$24.50 |
$1,042,676 |
D/D |
42,173 |
67,167 |
|
- |
|
| Venteicher Robert |
SVP, Technical Operations |
• – – |
2012-10-11 |
4 |
AS |
$27.00 |
$540,378 |
D/D |
(20,014) |
24,994 |
|
- |
|
| Venteicher Robert |
SVP, Technical Operations |
• – – |
2012-10-11 |
4 |
OE |
$24.50 |
$497,555 |
D/D |
20,014 |
45,008 |
|
- |
|
| Knapp Jeffrey H |
Chief Commercial Officer |
• – – |
2012-10-10 |
4 |
AS |
$25.00 |
$389,450 |
D/D |
(15,014) |
13,125 |
|
- |
|
| Knapp Jeffrey H |
Chief Commercial Officer |
• – – |
2012-10-10 |
4 |
OE |
$24.50 |
$345,450 |
D/D |
14,100 |
28,139 |
|
- |
|
| Duliege Anne-Marie |
Chief Medical Officer |
• – – |
2012-10-10 |
4 |
AS |
$24.00 |
$232,896 |
D/D |
(9,704) |
23,125 |
|
- |
|
| Venteicher Robert |
SVP, Technical Operations |
• – – |
2012-10-10 |
4 |
AS |
$24.00 |
$1,254,801 |
D/D |
(50,911) |
24,994 |
|
- |
|
| Venteicher Robert |
SVP, Technical Operations |
• – – |
2012-10-10 |
4 |
OE |
$5.83 |
$680,769 |
D/D |
50,911 |
75,905 |
|
- |
|
| Venteicher Robert |
SVP, Technical Operations |
• – – |
2012-10-09 |
4 |
AS |
$23.00 |
$251,574 |
D/D |
(10,938) |
24,994 |
|
- |
|
| Venteicher Robert |
SVP, Technical Operations |
• – – |
2012-10-09 |
4 |
OE |
$15.00 |
$164,070 |
D/D |
10,938 |
35,932 |
|
- |
|
| Knapp Jeffrey H |
Chief Commercial Officer |
• – – |
2012-10-09 |
4 |
AS |
$23.24 |
$278,880 |
D/D |
(12,000) |
14,039 |
|
- |
|
| Knapp Jeffrey H |
Chief Commercial Officer |
• – – |
2012-10-09 |
4 |
OE |
$21.74 |
$260,880 |
D/D |
12,000 |
26,039 |
|
- |
|
| Venteicher Robert |
SVP, Technical Operations |
• – – |
2012-10-05 |
4 |
AS |
$22.00 |
$259,358 |
D/D |
(11,789) |
24,994 |
|
- |
|
| Venteicher Robert |
SVP, Technical Operations |
• – – |
2012-10-05 |
4 |
OE |
$10.99 |
$129,561 |
D/D |
11,789 |
36,783 |
|
- |
|
| Orwin John A |
CEO |
• • – |
2012-10-05 |
4 |
AS |
$22.50 |
$937,440 |
D/D |
(41,664) |
92,000 |
|
- |
|
| Orwin John A |
CEO |
• • – |
2012-10-05 |
4 |
OE |
$6.90 |
$287,482 |
D/D |
41,664 |
133,664 |
|
- |
|
| Venteicher Robert |
SVP, Technical Operations |
• – – |
2012-10-04 |
4 |
AS |
$22.00 |
$2,200 |
D/D |
(100) |
24,994 |
|
- |
|
| Venteicher Robert |
SVP, Technical Operations |
• – – |
2012-10-04 |
4 |
OE |
$10.99 |
$1,099 |
D/D |
100 |
25,094 |
|
- |
|
| Venteicher Robert |
SVP, Technical Operations |
• – – |
2012-10-02 |
4 |
AS |
$21.14 |
$10,739 |
D/D |
(508) |
24,994 |
|
- |
|
225 Records found
|
|
Page 2 of 9 |
|
|
